Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Angiogenesis
Studies from B. Escudier et al provide new data on angiogenesis
March 24th, 2009
According to a study from Villejuif, France, "The mammalian target of rapamycin (mTOR) is a strategic target for cancer therapy. This serine/threonine kinase is involved in the integration of signals from numerous growth factors and nutrients and regulates the mRNA translation of proteins that mediate cell growth, proliferation, metabolism, and angiogenesis." "The pathways which impact mTOR signaling are dysregulated in many cancers, including renal cell carcinoma (RCC). In addition, for many patients, the pathogenesis of RCC is related to loss of function of the von Hippel-Lindau (VHL) gene, resulting in inappropriate accumulation of the hypoxia-inducible factor, HIF-1...
Source: Cancer Weekly (2009-03-24)
|
